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Abstract: The liver represents the major site of drug metabolism in humans. The developmental changes that occur in the liver’s 
metabolic activity during fetal life and in the perinatal period are at the basis of the varied sensitivity of human newborns to many drugs. 
The decreased capacity of the fetal and newborn liver to metabolize, detoxify, and excrete drugs - total cytochrome P450 content in the 
fetal liver being 30% to 60% of adult values - may explain the prolonged actions of many drugs in the newborn, as well as less their 
potential toxicity. On the other hand, the low levels of phase I (activation) enzymes, producing more polar reactive and often toxic 
metabolites, could explain the lower incidence of adverse effects of some drugs reported in newborns. Moreover, the greater capacity of 
newborns to synthesize glutathione is at the basis of their ability in inactivating many toxic metabolites. Here we review the acute and 
chronic liver toxicity due to the most widely used drugs in the neonate. We will discuss in detail the biochemical profile of the fetal and 
neonatal liver, and the toxic metabolites formed during the metabolism of the most widely used drugs in the neonate. The histological 
picture of liver disease related to the therapeutic use of drugs will be discussed, with particular emphasis on the mode of cell death 
involved in hepatitis induced by different drugs most frequently utilized in the neonatal intensive care units. 
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INTRODUCTION 
The liver plays a central role in the metabolism of xenobiotics, 
including drugs, being mainly responsible for their metabolism and 
excretion. The metabolism of the vast majority of drugs gives rise, 
inside the hepatocytes, to the generation of toxic metabolites, 
predisponing the liver to drug toxicity [1]. Hundreds of drugs have 
been implicated in the aetiology of hepatotoxicity and associated 
with adverse events characterized by a primary liver involvement 
[2]. The clinical picture of hepatitis associated to drugs, recently 
named drug-induced liver injury (DILI) [3] or drug-induced liver 
disease (DILD) [4], ranges in severity from a mild and reversible 
increase in serum levels of transaminases up to the insurgence of 
acute fulminant hepatic failure [5].  
As for drug metabolism, the human neonate should be 
considered a very special patient population, a unique drug 
recipient [6], given the state of immaturity at birth and the daily 
evolution of many metabolic functions, including drug carriers at 
the intestinal level, intracellular transporters in the enterocytes, 
carriers in blood, drug metabolizing enzymes in liver cells, and 
renal function, all factors which have a great influence on the 
efficacy and toxicity of medications [7]. As a consequence of the 
incomplete maturity of so many functions at birth, bioavailability of 
drugs in newborns and, in particular, in preterms, shows marked 
differences as compared with that observed in adults, regarding 
absorption, distribution, metabolism and excretion [8]. 
Developmental aspects should be considered even regarding drug 
conjugation with special reference to glucuronidation, due to the 
significant decreased ability of neonates to metabolize the vast 
majority of drugs [9, 10].  
Pharmacokinetic differences between neonates, children and 
adults may play a relevant role in the age-related differences of 
adverse effects to drugs between these different populations. For 
some drugs there is an increased risk of adverse effects in neonates, 
for others a protection against hepatotoxicity seems to be present 
[11, 12]. Recent studies aimed at evaluating pediatric drug dosing 
guidelines for intensive care newborns, underline the scarcity of 
drug studies in this population, and lay stress on the widely 
different dosing guidelines in the four most commonly used drug 
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formularies in the intensive care units, regarding doses per 
kilogram, dose description and dosing regimen [13]. 
Recently, other factors that may have a potential influence on 
pharmacokinetic of drugs have been proposed. Among them, 
biological rhythms, including the sleep-wake, the circadian 
temperature rhythms, and the circadian secretion of many hormones 
have been suggested to deeply influence the action and toxicity of 
drugs [14, 15]. Perinatal asphyxia influences drug toxicity and 
seems to increase aminoglycoside ototoxicity [16]. Therapeutic 
whole body hypothermia for the treatment of hypoxic-ischemic 
encephalopathy in neonates has been shown to influence the 
metabolism of many drugs. Phenobarbital administered under 
hypothermia resulted in higher plasma concentrations and longer 
half-life than in normothermic newborns, suggesting a lower rate of 
liver metabolism by the hypothermic liver [17]. Moreover, delayed 
time of maximal serum concentration, considerably higher serum 
values and lower total body clearance, were reported for topiramate 
in neonates under whole body hypothermia, suggesting lower 
absorption and elimination when compared to normothermic 
newborns [18]. Size and gestational age at birth should also be 
taken into account when drug dosing and toxicity are considered: 
the pharmacokinetic parameters in the premature neonates have 
been shown to differ so significantly from those of full term 
newborns [19], leading to the recent development of a new research 
field defined developmental pharmacology, whose goal is the study 
of the impact of birth and of gestational age on drug response in the 
perinatal period [20]. Developing pharmacology should also induce 
neonatologists working in Neonatal Intensive Care Units (NICUs) 
to continuously adapt drug dosage for a single newborn, given the 
daily maturation of his/her drug metabolizing system, with relevant 
consequences in the pharmacokinetics of many drugs.  
The purpose of this article is to provide a brief review of the 
pharmacokinetic differences between neonates and adults, to show 
the peculiarities of liver function at birth, particularly in preterm 
infants, the toxic mechanisms of liver injury in the perinatal period, 
and the histological and clinical markers of liver disease due to the 
most frequently utilized drugs in NICUs. 
PECULIARITIES OF PHARMACOKINETICS IN THE 
PERINATAL PERIOD 
1. Absorption and Bioavailability of Drugs 
Clinical pharmacokinetics in the newborn, and in particular oral 
absorption of many drugs, may be modified by the different gastric 
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and intestinal pH, by differences in the gastrointestinal emptying 
time, by the peculiar composition of the gastrointestinal flora at 
birth, and by the decreased enzyme activity in the immature 
intestinal epithelium in the perinatal period [21, 22]. The gastric pH 
ranges from 2.3 to 3.6 in full term newborns, from 6 to 8 in preterm 
infants, and reaches the typical adult values (1.4 to 2.0) by the age 
of 1 to 2 years. As a consequence, the gastric absorption of many 
drugs including phenobarbital, that depends on the gastric pH, is 
always decreased at birth, and may show significant differences 
between preterm and full term newborns. The lower the pH relative 
to the pKa, the greater fraction of protonated drug is found. As a 
result, a weak acid at acid pH will be more lipid-soluble because it 
is uncharged and uncharged molecules move more readily through 
a lipid (nonpolar) environment, like the enterocyte membrane, than 
charged molecules. Similarly, a weak base at alkaline pH will be 
more lipid-soluble because at alkaline pH a proton will dissociate 
from molecules leaving them uncharged and again free to move 
through lipid membrane structures. Since lipid diffusion depends on 
adequate lipid solubility, drug ionization reduces a drug's ability to 
cross a lipid bilayer. Drugs are, in general, weak acids or bases. A 
weak acid is a neutral molecule that dissociates into an anion 
(negatively charged) and a proton (a hydrogen ion). For example, 
neutral aspirin acetylsalicylic acid (C8H7O2COOH), is in 
equilibrium with its anion (C8H7O2COO-) and a proton (H
+
). In 
particular, developmental changes have been reported for 
phenobarbital absorption rate in the gastrointestinal tract in 
neonates, with low absorption levels at birth and marked increase, 
up to ten times, in the perinatal period. On the contrary, 
percutaneous absorption is very high at birth, and decreases only 
slowly at the adult levels, that are reached by 3 to 5 years of life. 
Therefore, skin application of drugs, in particular of steroids, to 
newborns requires special attention [23]. An example of 
peculiarities in neonatal pharmacokinetics and pharmacodynamics 
is presented in (Table 1). 
2. Blood Transport 
Drug distribution is affected by the low serum protein levels 
typical of neonates, which show a decreased binding capacity to the 
vast majority of drugs, significantly altering the ratio of unbound to 
total plasma concentration of multiple drugs. The serum protein 
binding rate for acidic drugs has been shown to reach adult values 
by around 1 year of life, whereas for basic drugs the adult levels are 
reached by 3 to 4 years [23]. As a consequence, in the neonate, 
unbound plasma concentrations are needed for therapeutic drug 
monitoring, to prevent dose-dependent adverse effects. A recent 
study carried out on epileptic neonates and infants, clearly showed 
that the serum concentrations of unbound valproic acid (VPA) in 
newborns noticeably differed from the reference adult values, 
suggesting that the unbound concentration of VPA, as well as that 
of other drugs, should be explicitly determined via therapeutic drug 
monitoring activities, due to the poor applicability of estimation 
methods for adults [24]. 
3. Distribution 
The distribution volumes of newborns show marked 
peculiarities as compared to distribution volumes in adults, which 
are normally reached around 3 to 5 years of life. As for the body 
fat, it has been calculated to be 12% in full term newborns, ranging 
from 3 up to 12% in preterms, as compared to 18% in adults. The 
extracellular water volume is 60%, compared to 20% in adults, 
whereas the total body water has been estimated around 75% for 
neonates and 50% for adults. As a consequence of these marked 
differences, the distribution volume in the perinatal period is 
significantly larger for hydrophilic drugs, and smaller for lipophilic 
drugs than in adults [23]. In clinical practice, hydrophilic drugs 
with a high volume of distribution in adults should be normalized to 
body weight in neonates, whereas hydrophilic drugs with a low 
volume of distribution in adults should be normalized to body 
surface area [25]. 
4. Hepatic Metabolism of Drugs in the Neonate 
The human liver plays a central role in the uptake, transport, 
metabolism and excretion of the vast majority of xenobiotics, 
including drugs [26]. The hepatocytes, highly polarized cells with 
distinct sinusoidal and biliary poles, have an essential function in 
selectively removing lipid-soluble drugs weighing more than 500 
daltons from the sinusoidal lumen and, utilizing specific active 
transporters located on the cell membrane, allow their passage 
across the hepatocytic membrane into their cytoplasm [27]. The 
second step of the interaction between drugs and liver cells is 
represented by binding of internalized drugs to cytosolic proteins 
and chaperons, that operate the intracellular drug transport towards 
the enzymes of the drug metabolizing system [28]. These can be 
subdivided into two main groups: phase 1 enzymes are involved in 
reactions of oxidation, hydroxylation, and other reactions mainly 
mediated by cytochrome P-450 (CYP); phase 2 enzymes are mainly 
involved in esterification reactions, that originate conjugates with 
sulfate, glucuronic acid, amino acids and glutathione molecules, 
generally resulting in increased water solubility, decreased 
pharmacologic activity and eventually detoxification of xenobiotic 
compounds [29]. The final step of the hepatic drug metabolism is 
characterized by the excretion of drugs, their metabolites and their 
conjugates into bile or into the sinusoidal circulation. These 
pathways, recently referred to as phase 3 of the hepatic drug 
metabolism, include the multidrug resistance (MDR) protein and 
the multidrug resistance-related proteins [30]. 
However, under conditions of increased levels of the drug, 
when phase 1 and phase 2 enzymes activity is not well balanced, in 
the presence of genetic alterations determining changes in the 
expression of hepatobiliary drug-transporters or of drug-
metabolizing enzymes, the same mechanisms may cause the 
production of toxic metabolites, leading to DILI [31].  
Pharmacokinetic and pharmacodynamic differences have been 
reported in recent years, between children, particularly newborns 
and preterm infants, and adults [8] as for drug metabolism. The 
Table 1. Anatomo-Functional Immaturity and Management of Antibiotics in the Newborn 
 
 Modified Parameter Pharmacokinetics Example Practical Consequence 
High Extracellular Fluids  Distribution Volume  Peak Gentamicin  Dosage per dose (Kg/dose) 
Low Serum Proteins  Drug-Proteins binding   Free Fraction Ampicillin Dose Reduction 
Immaturity of Liver Enzyme  Metabolism  Clearance Cloramphenicol Dose Reduction 
Renal Immaturity (Glomerular and Tubular)  Excretion  t1/2 Gentamicin Reduction of Frequence of Administration 
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metabolic profile of the neonate has been shown by several studies 
to significantly differ in the absorption, distribution, metabolism 
and excretion of many drugs, due to marked biochemical 
differences in sulphation, glucuronidation, conjugation and 
elimination [7, 10, 32-34]. It has been shown that certain 
biotransformation pathways, including hydroxylation and 
glucuronidation, demonstrate only limited activity at birth [35], 
whereas other pathways, such as sulphate or glycine conjugation, 
appear very efficient, more than in adult subjects, in the newborn 
[33]. In clinical practice, this physiological diversity has important 
consequences on drug dosing for different drugs. Children need 
weight-corrected doses, higher than adult doses, for drugs that are 
metabolically eliminated solely by specific CYP isoenzymes, 
including CYP1A2, CYP2C9 and CYP3A4. In contrast, weight-
corrected doses for drugs eliminated by renal excretion or 
metabolism involving N-acetyltransferase 2, or uridine diphosphate 
glucuronosyltransferase (UDGT) are similar in newborns and adults 
[36].  
In addition, newborns present a greater capacity, when 
compared to adults, to sinthesize glutathione, thereby more 
effectively inactivating toxic metabolites produced by the activity 
of phase 1 enzymes on many drugs [35]. Some enzyme activity, 
including thymidine kinase and ornithine decarboxylase, is high 
during foetal life and at birth, and falls during the postnatal period. 
On the contrary, other liver enzymes, including aspartate 
aminotransferase, show a low expression in the human foetus, but 
increase their expression after birth [37]. Another group of liver 
enzymes is expressed only in the perinatal period, and increases 
after birth. 
These developmental marked modifications of the machinery 
utilized by hepatocytes in the metabolism of drugs place the 
newborn, the preterm infant and the developing foetus at a different 
risk from drug-toxicity as compared to adults, and are responsible 
for the different effects of the same drug on liver at various stages 
of development. For example, the lower expression in the newborn 
of the liver enzymes involved in glucuronide conjugation, has been 
proposed to be possibly responsible for the gray infant syndrome 
from chloramphenicol [35].  
The balance between activation (phase 1 enzymes) and 
detoxification reactions (phase 2 enzymes) is crucial in the 
elimination of drug metabolites [38]. Many factors may influence 
this critical balance, including some enzymatic inducers, that may 
affect disproportionately phase 1 or phase 2 enzymes. 
Taken all together, it becomes apparent that children cannot be 
regarded as “small adults” with respect to drug therapy: they often 
need a different fraction of drug per Kg of body weight as 
compared to adults. For example as for digoxin, a drug excreted by 
glomerular filtration but also secreted by the tubular renal cell, 
newborns need threefold higher doses per Kg body weight than 
adults [39]. 
The frequent observation in clinical practice of marked 
interindividual differences in drug responses among neonates, and 
particularly among preterms, has given birth to the concept of 
“tailor made” drug therapy in neonatology, i.e. a customized drug 
therapy based on the peculiar metabolic system of each neonate, 
irrespectively of the “general”, often adult-related therapeutic 
protocols [7]. 
5. Renal Excretion and Metabolism 
A thorough examination of the expression pattern of the main 
drug transporters in the newborn kidney, as well as in all stages of 
human development, has yet to be carried out. As a consequence, 
data on the functional maturation of the drug transporters’ system in 
preterms, in low birth weight newborns, and in neonates mainly 
depend, in clinical practice, on the ability of the neonatologist to 
investigate and understand the degree of functional maturation of 
each neonate, by performing “in vivo” specific pharmacokinetic 
analyses in order to establish the correct drug dosage in every single 
newborn. Given the slower rate of biotransformation activity typical 
of the newborn liver, which includes slower rate of 
biotransformation and slower overall elimination of drugs, in the 
neonate drug elimination relies heavily on renal excretion [7]. 
DRUG INDUCED LIVER INJURY (DILI) 
1. Pathogenesis of Drug-Related Liver Injury in Newborns 
The biotransformation of xenobiotics, including drugs, in the 
human liver at birth presents many peculiar features as compared to 
adults, which result in a different balance between the two most 
important phases of the hepatic drug metabolism: bioactivation, 
mainly due to the action of phase 1 enzymes, and detoxification, of 
which phase 2 enzymes are responsible. As previously stated, the 
balance between these factors is not stable in the newborn 
mentioned, but it changes day by day according to the rapid 
development of phase 1 and phase 2 enzymes in the postnatal 
period [40]. Temporal dynamics, individual polymorphisms, and 
balance between phase 1 and phase 2 enzymes have been indicated 
as the main factors having a profound impact on drug 
biotransformation and susceptibility to adverse toxic effects [28].  
The CYP (cytochrome P-450) gene superfamily found in both 
eukaryotes and prokaryotes has grown from a putative ancestral 
gene formed more than 3.5 billion years ago [41]. So far, 79 gene 
families have been described: of these, 14 are found in mammals, 
families 1-4 being the most important ones in the metabolism of 
xenobiotics in man [42]. The ontogeny of the most important CYPs 
taking part in drug metabolism in human liver is characterized, at 
birth, in general by their markedly decreased activity, total CYPs 
content in fetal liver being estimated between 30% and 60% of 
adult values [43, 44]. But differences between neonates and adults 
are not simply quantitative. It has been shown that certain 
biotransformation pathways, including hydroxylation and 
glucuronidation, demonstrate very limited activity at birth, whereas 
other pathways, such as sulphate or glycine conjugation, appear 
very efficient in the newborn [33]. Biotransformation of most of the 
commonly used drugs is catalyzed by CYPs and uridine 
diphosphate glucuronosyltransferase (UGT) enzymes [8]. The 
human hepatic CYP is approximately composed of 50 isoenzymes, 
grouped into three main families, CYP1, CYP2, CYP3 [44]. Eight 
isoenzymes are mainly involved in the metabolism (oxidation) of 
most drugs (CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, 
CYP2D26, CYP2E1, and CYP3A4). The most abundant isoenzyme 
in the human liver is CYP3A4, which accounts for about 30% of 
the total liver CYP, and is generally thought to be involved in the 
oxidation process of more than 50% of drugs [45]. CYP2D6 
accounts for 2% or less of the hepatic CYP, but it is responsible for 
the oxidative metabolism of approximately 12% of clinically 
relevant drugs [46]. Moreover, CYP2D6 activity was detectable in 
neonates only by 2 weeks of postnatal age, with values at birth no 
greater than 3 to 5% the levels observed in the adult liver [47]. 
Some members of CYP families are detected early in 
organogenesis, whereas others are not detectable at birth and 
develop at different rates in the postnatal period. Some examples of 
temporal switching in the perinatal period: CYP3A7 is highly 
expressed in the foetal liver, and disappears after birth; CYP3A4, 
undetectable during gestation, dramatically increases at 1 postnatal 
week, and reaches adult levels around 1 month after birth. The 
knowledge of these differences in the different activity of the 
different CYP family members in neonates, may explain the 
increased risk of adverse effects of some drugs in the newborn. The 
low content of CYP3A4 in the neonate has been reported to be 
mainly responsible for the impaired metabolism of cisapride in the 
perinatal period, resulting in accumulation of the drug and cardiac 
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toxicity [48]. The classes of drug substrates of CYP3A4 enzyme 
include antibiotics, antivirals, antifungals, immunomodulators, 
benzodiazepines, proton pump inhibitors, steroids and 
acetaminophen [28]. As a consequence, neonates, in spite of the 
high ratio of liver size to body size, often show a decreased ability 
to metabolize the vast majority of drugs routinely utilized in a 
NICU, drugs which are eliminated through CYP-dependent 
metabolism. The low levels of CYP enzymes, and in particular of 
CYP3A4 isoform, in the newborn make the neonate particularly 
susceptible to overdosage-related toxicity from many drugs, due to 
the blocking of drug excretion, which necessitates the action of 
phase 1 enzymes, aimed at rendering more hydrophylic (and 
excreatable) the lipophylic drugs. As a consequence, the neonate 
shows a prolonged half-life for most drugs [37]. 
The vulnerability of the human liver to drug toxicity in the 
perinatal period is not restricted to phase 1 enzymes deficiency, 
glucuronide conjugation capacity being markedly reduced at birth 
[35]. Glucuronidation represents one of the main detoxification 
pathways in humans, and undergoes relevant developmental 
changes during the perinatal period. In children younger than 2 
years, and in particular in neonates and in preterm infants, the 
hepatic glucuronidation activity has been demonstrated to be 
markedly reduced [49]. Different classes of drugs, including 
ibuprofen and steroid hormones, are normal targets for the 
detoxification action of UGT. The low UGT activity in the neonatal 
liver might be responsible for the accumulation of reactive 
metabolites originating from different drugs by the action of phase 
1 enzymes, which, in the absence of adequate glucuronidation 
activity, could not be excreted and could accumulate inside liver 
cells, causing lipid peroxidation, interfering with protein synthesis, 
damaging plasma membranes and inducing cell death Fig. (1).  
 
Fig. (1). Activity of phase I enzymes of the drug metabolizing system may 
allow drug elimination by increasing water solubility of the drug, but may 
also bioactivate the drug, giving rise to toxic metabolites. 
 
Bile formation is essential for the excretion of many 
xenobiotics, including the glucuronide and the glutathione 
conjugates of many drugs [50]. This essential function predisposes 
the human liver to cholestatic hepatocellular injury, which accounts 
for almost half of all hepatic drug toxicity including the neonatal 
period [29, 51]. The target of injury caused by the toxic action of 
drugs, or their active metabolites, can vary, from the hepatocyte, to 
the bile canaliculus, resulting in intrahepatic cholestasis, or to a 
obstructive cholangiopathy where the initial site of injury is located 
at various levels of the biliary tree [52, 53]. The ability to 
synthesize and excrete bile components, including bilibirubin and 
bile acids, is immature in the neonate, and, when associated with 
low glucuronidation activity, may favour the insurgence of 
physiologic jaundice. Taken all together, these developmental 
changes place the developing fetus and the preterm infant at 
differential risk for cholestasis from toxic injury caused by different 
drugs [37]. 
Another factor to be taken into consideration when approaching 
to drug metabolism and toxicity in the neonate, is represented by 
genetic polymorphisms, which may profoundly influence 
expression and function of drug-metabolizing enzymes in different 
subjects, resulting in marked interindividual differences in 
metabolism and in the ability of excretion of specific drugs [28]. 
Interindividual differences in drug responses in clinical practice in 
NICU centers can be attributed to polymorphisms in genes 
encoding drug-metabolizing enzymes [54] and drug transporters 
[55], resulting in a high variability of the individual response to a 
drug in terms of efficacy and toxicity. All CYP enzymes, with one 
exception, are polymorphic, particular alleles causing qualitative 
and/or quantitative interindividual differences in the enzymatic 
activity and in the metabolism of specific drugs. Genetic 
polymorphisms of CYP enzymes have been proposed as one of the 
factors that contribute to the pharmacokinetic variability of drugs, 
allowing to identify extensive metabolizers and poor metabolizers, 
with major clinical implications for drug dosing and drug response 
[56]. Among the different CYP isoforms, CYP2D6 is highly 
polymorphic, with more than 80 known alleles, several of which 
have significant functional impact. 14 CYP2D6 alleles, that account 
for more than 90% of the variability observed, have been identified 
in different populations [57]. Polymorphisms have also been 
reported for phase 2 enzymes. UGT isoforms have been implicated 
as principally responsible for the interindividual variability in 
acetaminophen glucuronidation and for the marked interindividual 
variability in susceptibility to acetaminophen toxicity observed in 
clinical practice [58].  
2. Clinical Presentation and Pathological Findings of DILI in 
Neonates 
DILI is an important cause of potentially severe acute and 
chronic liver injury, occurring at any age and following the 
administration of more than 300 drugs [59], 30% being associated 
with disproportionally higher reporting frequency of liver injury 
[2]. The clinical picture of DILI in neonates is mainly characterized 
by a subclinical onset, with mild modifications of biochemical tests 
of liver function, in the absence of any pathognomonic clinical 
symptom. The diagnosis of DILI in neonates is, in the vast majority 
of cases, one of exclusion, and is confirmed after clinical 
improvement following discontinuation of the causative drug. 
Complete recovery occurs in the majority of patients, but acute liver 
failure and death have been rarely reported. Clinically and 
histologically, DILI can mimick any known liver disease of other 
origin, in the absence of any pathognomonic feature [60]. Diagnosis 
of DILI is therefore challenging, with considerable interobserver 
variability in assessing causality [61]. Risk factor ascertainment and 
early detection strategies have been proposed during the years [62, 
63], and significant initiatives such as the Drug-Induced Liver 
Injury Network (DILIN) have been established with the aim of 
advancing understanding of DILI and favoring a prompt diagnosis 
of the disease [64]. A statistically significant relationship has been 
observed between the daily dose of oral medicines and reports of 
liver failure due to DILI [65]. The development of acute hepatitis in 
patients with a diagnosis of DILI may be severe, being associated 
with a 9 to 12% mortality rate: patients with severe coagulopathy or 
encephalopathy are referred for potential liver transplantation [66].  
Hepatotoxic agents may be classified as intrinsic and 
idiosyncratic, also defined as facultative [67]. Hepatotoxicity due to 
intrinsic drugs occurs in every subject exposed to a proper toxic 
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dosage, is dose-dependent and may be reproduced in experimental 
animals. Acetaminophen is the typical intrinsic hepatotoxin. 
Idiosyncratic adverse reactions to drugs, the vast majority in 
clinical practice, are unpredictable, and occur in subjects who, for 
different reasons, do not tolerate that specific drug. These reactions 
are often explained by the inability of the subject to correctly 
metabolize the compound, due to a congenital reduced activity or to 
the absence of a peculiar enzyme, resulting in the accumulation of 
the drug and/or of its toxic metabolites.  
In clinical practice, adverse liver reactions to drugs are mainly 
classified as acute and chronic [68]. Acute hepatic injury is 
characterized by a cytotoxic injury with prominent elevation of 
transaminases, or by cholestatic injury, resembling obstructive 
jaundice. Chronic drug-related liver disease may be 
indistinguishable, even at histology, from a viral chronic hepatitis. 
The association, in the liver biopsy, of lymphocytic infiltrate with 
unexplained steatosis and/or bilirubinostasis, in the absence of viral 
markers, might induce clinicians to investigate the possibility of 
toxicity due to drugs, discontinuation of which is frequently 
followed by resolution of liver disease.  
3. Histological Changes in DILI 
Liver disease caused by adverse reactions to drugs may be 
classified according to the elementary lesions observed, at 
histological level, in liver biopsies from the affected patients. Drugs 
may cause derangement of one or more of the multiple functions of 
the hepatocytes: bile formation and excretion, synthesis of proteins, 
trace metals metabolism, regulation of blood glucose and lipid 
metabolism.  
Cholestasis is one of the typical consequences of drug 
hepatotoxicity [26]. The morphological cholestatic lesions are 
bilirubinostasis, defined as the accumulation in the hepatocytes 
and/or in bile canaliculi of bile plugs, and cholatestasis, i.e. the 
accumulation of bile salts resulting in a process of feathery 
degeneration of hepatocytes and leading to bile acid-mediated 
apoptosis. Bilirubinostasis and cholatestasis are the principal 
morphological signs indicating the interference of a drug on bile 
formation and excretion. The reduced capacity to synthesize and 
excrete bile, typical of every newborn, makes the neonate 
particularly susceptible to cholestasis from toxic injury due to drugs 
[69].  
A very frequent elementary lesion observed in liver cells, due to 
adverse drug reaction, is cell death, including apoptosis and 
necrosis [5]. Apoptotic cell death is characterized by the appearance 
of apoptotic globules, eosinophilic roundish globules that undergo 
phagocytosis by Kupffer cells [70]. Liver cell necrosis is 
characterized by ballooning of hepatocytes, followed by rupture of 
the cell membrane and lysis, with immission of hepatocytic 
enzymes, including transaminases, into the sinusoidal lumen. 
Oxidative stress is one of the main mechanisms that mediate drug-
induced liver cell death. Many chemicals, including many drugs, 
have been shown to increase the production of free radical species, 
leading to hepatocyte cell death [71]. Cell necrosis, in the majority 
of drug-related liver disease, is characterized by a zonal 
distribution, involving the perivenular (zone 3), the periportal (zone 
1) or the mid-zone, depending on the drug involved. Perivenular 
necrosis is the most common type, and can be the result of 
hepatotoxicity due to many toxins, including aflatoxins, 
ketoconazole, para-aminosalicylic acid, valproic acid, rifampicin, 
indomethacin, and paracetamol [72]. Periportal (zone 1) necrosis is 
caused by a few number of drugs. The perivenular location of the 
hepatocellular lesions caused by many drugs, including 
paracetamol, might reflect the high concentration in zone 3 of the 
enzymes responsible for the conversion of these drugs into 
hepatotoxic metabolites [73].  
 
After an episode of acute hepatocellular necrosis, cell debris are 
phagocytosed by Kupffer cells, which contain Pas-positive diastase-
resistant ceroid pigment, often associated with Perls-positive 
haemosiderin. Only rarely, hepatocytic necrosis may be diffuse, 
originating bridging necrosis, with severe alterations of the liver 
architecture.  
Another very frequent lesion in drug-related liver disease is 
steatosis, i.e. fat accumulation inside hepatocytes, appearing as 
clear droplets different in size, ranging from very small 
(microvesicular steatosis) to large vacuoles occupying the entire 
cytoplasm and pushing the nucleus at the cell border 
(macrovesicular steatosis). Steatosis has been associated with a 
large number of drugs, together with other forms of liver cell 
damage, including apoptosis and cell necrosis [74]. Microvesicular 
steatosis in drug-related liver disease has been mainly associated 
with fatal salicylate intoxication in children, as a typical finding of 
the Reye’s syndrome [75]. Microvesicular steatosis has been also 
reported in association with tetracycline hepatotoxicity [76-78]. 
Macrovesicular steatosis has been observed in DILI due to a large 
number of drugs, including ibuprofen, indomethacin, paracetamol, 
rifampicin, sulphasalazine, and zidovudine [79].  
Inflammatory lesions may be also present in liver biopsies from 
children with DILI and, when associated with steatosis, the 
definition of steatohepatitis may be used. Lymphocytes are the most 
common inflammatory cells observed in DILI: they are mainly 
detected in portal tracts and, in some cases, they show adhesion to 
the membrane of periportal hepatocytes, leading to apoptosis and 
cell necrosis of the hepatocytes of the periportal lamina, also known 
as piecemeal necrosis.  
The observation, at histology, in DILI of piecemeal necrosis, 
associated with a dense lymphocytic infiltrate and with plasmacells 
in clusters, suggests an immunoallergic response. An immunologic 
mediation of drug-induced hepatitis has been reported with 
antibiotics, including amoxicillin, clavulanic acid, and sulfonamides 
[80]. In rare instances, polymorphonuclear cells may also be 
observed, both in portal tracts and inside the liver acinus.  
Liver Disease due to the Most Widely Utilized Drugs in 
Newborns 
4.1. Antibiotics 
Due to the high susceptibility to infections of newborns, 
antibiotics are the most widely utilized drugs in neonates, the best 
initial therapy against a suspected systemic infection remaining, as 
several years ago, the association of ampicillin and gentamicin [81]. 
Moreover, in recent years, antibiotics have been proposed for 
different indications in the antibacterial activity: erythromicin for 
the treatment of gastrointestinal dismotility, and for the prevention 
of cholestasis in preterm infants under parenteral nutrition; 
azithromycin, because of the combined antibiotic and 
antiinflammatory effects, in the prevention of bronchopulmonary 
dysplasia in low birth weight infants [82].  
DILI is caused by a wide array of medications, including herbal 
supplements and dietary supplements, but antibiotics are the single 
largest class of agents that cause DILI [83]. A recent clinical update 
on DILI showed that the most common drugs leading to 
hepatotoxicity in the United States, at every age, are antibiotics 
[84]. The explanation for the frequent association between 
antibiotics and hepatotoxicity could be related to the widespread 
prescription of these drugs, whereas the relative risk of antibiotic-
related hepatotoxicity is thought to be low [85]. Multiple 
mechanisms of antibiotic-induced liver injury have been implicated, 
including apoptosis activated by TNF-alpha, inhibition of 
mitochondrial function, and neoantigen formation. In extremely low 
birth weight infants, prolonged duration of the empirical antibiotic 
treatment has been associated with increased rates of necrotizing 
enterocolitis and death [86].  
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Penicillins 
Among the penicillins, ampicillin only rarely has been 
associated with hepatotoxicity [87], but the association amoxicillin-
clavulanate probably represents the most common cause of 
cholestasis related to therapy with antibiotics [88, 89], and one of 
the four most common causes of DILI [85, 90]. This compound is a 
combination of amoxicillin trihydrate, an aminopenicillin, and 
potassium clavulanate, a beta-lactamase inhibitor, used to treat a 
broad-spectrum of bacterial infections, especially resistant strains. 
Its molecular weight is 564.56 Da, and the molecular formula is 
C24H28N4O10S.  
In a study of 153 patients of different ages affected by 
amoxicillin-clavulanic acid-related hepatitis, liver injury was 
classified to be hepatocellular in 35 (22.8%), cholestatic in 24 
(15.7%), and mixed in 83 patients (54.5%) [91]. In some cases, 
acute hepatitis showed progression to cirrhosis [92], but in the 
majority of cases, liver injury was not severe and resolved after 
prompt withdrawal of the drugs [93, 94]. The incidence of 
amoxicillin-clavulanate induced hepatotoxicity has been estimated 
to be 9.9 per 100,000 users, representing between 12.8% to 14% of 
the reported cases of DILI [95]. At histology, hepatocytic and 
canalicular bilirubinostasis appears to be more pronounced in 
perivenular regions (zone 3), whereas portal tracts show 
lymphocytic infiltrate associated with bile duct lesions [96]. Only 
rare cases of immuno-allergic hepatitis related to amoxicillin-
clavulanic acid therapy have been reported, all characterized, at 
liver biopsy, by portal and intraacinar eosinophilic infiltration [97]. 
The vast majority of cases of DILI related to amoxicillin-clavulanic 
acid therapy have been reported in adults, even though occasional 
reports of hepatotoxicity associated with these drugs have also been 
described in children. In pediatric patients, the adverse effects on 
liver were characterized by a rapidly progressive liver disease with 
severe cholestasis due to the necroinflammatory lesions of the 
intrahepatic bile ducts [98]. In some children, therapy with 
amoxillin associated to clavulanic acid has been reported to cause 
the vanishing bile duct syndrome, a liver disease characterized by 
disappearance of the septal bile ducts in the majority of portal 
tracts, ending with severe disarrangement of the liver architecture 
[99]. That is very important to underline, according to many authors 
amoxicillin-clavulanic acid-related DILI might be underestimated, 
due to a frequent time interval between stopping the treatment and 
the first manifestations of liver disease, jaundice in most cases, after 
discontinuing treatment several weeks [100]. These observations 
might explain, at least in part, the rarity of reports of adverse effects 
related to this association in newborns. The frequency of jaundice 
due to other aetiologies, including immaturity of the bilirubin 
metabolizing machinery in neonates, particularly in preterms, 
associated with the absence of a strict relationship between the 
assumption of these drugs and the insurgence of adverse effects, 
could be at the basis of an underestimation of their toxicity in the 
perinatal period. Given that liver disease due to therapy with this 
association may be severe, and death in patients of different ages 
have been reported [101], caution should be taken when deciding to 
start therapy with amoxicillin associated with clavulanic acid in 
newborns. 
Flucloxacillin 
The penicillinase-resistent flucloxacillin ranks as the second 
highest cause of DILI in many countries [96]. Genetic-association 
studies have recently identified genotypes related to flucloxacillin 
hepatotoxicity [85]. 
Cephalosporins 
In spite of their high efficacy against most of the Gram positive 
and Gram negative pathogens commonly encountered in neonatal 
infections, cephalosporins, accordingly with the vast majority of 
neonatologists, should not be part of the initial empirical therapy in 
NICU centers, due to their toxicity in newborns [81]. In fact, 
overuse of cefotaxime in the first three days after birth has been 
associated with an increased risk of death [102] and neonatal 
candidiasis, especially in extremely low birth-weight newborns 
[103]. A reversible symptomatic biliary obstruction associated with 
ceftriaxone pseudolithiasis is well known to neonatologists [104, 
105]. The association of ceftriaxone and calcium-containing 
solutions in both term and premature infants has been reported to 
cause fatal reactions, due to calcium-ceftriaxone precipitates in 
lungs and kidneys. Ceftriaxone should not be utilized in 
hyperbilirubinemic neonates, especially prematures, given its 
ability to cause bilirubin displacement, producing an increase of 
free bilirubin and the decrease of unconjugated bilirubin [106]. 
Macrolides 
Among macrolides, erythromicin is considered a classical 
example of drug inducing cholestatic liver disease. Erythromicin 
causes jaundice in about 1-2% of adults taking the drug, but only 
rarely in children [88]. The histological picture of erythromycin- 
related DILI is characterized by bilirubinostasis, appearing as bile 
casts inside dilated bile canaliculi. Cholestatic features are often 
accompanied by portal lymphocytic infiltrate, with numerous 
eosinophils [107]. In recent years, concern has arisen regarding 
telithromycin, a new generation macrolide, frequently associated 
with severe adverse reactions, characterized by jaundice, fever, 
abdominal pain and ascites [95].  
Azithromicin hepatotoxicity typically causes intrahepatic 
cholestasis, evidenced at histology by the observation of 
bilirubinostasis in the cytoplasm of hepatocytes and of bile thrombi 
inside bile canaliculi [108].  
Aminoglycosides 
 (e.g. gentamicin, amikacin, netilmicin, tobramicin) are 
effective antibiotics against Gram-negative infection in neonates, 
which, in spite of their ototoxicity and nephrotoxicity [109], still 
remain the frontline antibiotic in developing countries, because of 
their efficacy and low cost, especially to treat tuberculosis [110].  
Gentamicin 
A mainstay in treating Gram-negative sepsis and often 
combined with a penicillin in NICU clinical practice, only rarely 
has been associated with hepatotoxicity, no hepatic adverse 
reactions being observed in the vast majority of treated patients 
[111]. In mice, gentamicin was found to enhance basal and 
lipopolysaccharide-stimulated hepatic and renal TNF-alpha mRNA 
levels, suggesting a possible role in potentiating the inflammatory 
response, beyond its traditional antimicrobial effect [112]. 
Recently, a study on gentamicin toxicity carried out in rats by the 
ingenuity pathway analysis, revealed liver toxicity in the vast 
majority of animals, along with the previously known kidney and 
heart toxicity [113]. Gentamicin-related liver toxicity has been 
hypothesized to be caused by the formation of a toxic metabolite, 
that localizes to the cytosolic fraction of liver cells [114]. The 
exposure of preterm and term neonates to toxic serum levels of 
gentamicin has been also related to the inability to account for the 
ontogeny of renal function and to adjust dosing regimens according 
to the actual glomerular filtration rate [115]. Comorbid conditions, 
such as perinatal asphyxia have been supposed to increase 
gentamicin toxicity in newborns [116], probably via the caspase-
dependent cell death pathway [16]. As for the type of cell death 
caused by gentamicin in liver cells, an electron microscopy study 
carried out in rats by injecting intramuscularly gentamicin once 
daily for 1, 2, 3 and 4 weeks successively, clearly showed the 
ability of gentamicin to induce severe mitochondrial alterations in 
the hepatocytes, followed by apoptotic cell death [117].  
Chloramphenicol 
Has been shown to be highly toxic in the newborn when given 
in excessive doses, causing a cardiovascular collapse associated 
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with the gray syndrome [118]. The explanation of chloramphenicol-
related toxicity is the delayed maturation of the hepatic drug-
metabolizing enzymes and, in particular, of glucuronyl transferase 
[119].  
4.2. Acetaminophen 
Acetaminophen, N-acetil-p-aminophenol, is the active 
metabolite of phenacetin, widely utilized in clinical practice due to 
its antipiretic and analgesic properties. Even though it is considered 
one of the most safe drugs, on the other hand acetaminophen is one 
of the most common causes of DILI in children [120]. It has been 
reported to be the most common cause of acute liver disease in 
children in the United Kingdom and the United States, accounting 
for 15% of all drug-induced acute hepatitis [121]. In another study 
carried out on 417 children younger than 5 years, the incidence of 
hepatotoxicity due to acetaminophen was 5.5%, as compared with 
29% in adolescents and adults [122]. In the United States, up to 
50% of acetaminophen-related cases of acute liver failure are 
thought to occur as the result of unintentional overdose [123], 
leading to the recent decision by the U.S. Food and Drug 
Administration to limit the dosage of acetaminophen to 325 mg in 
combination with prescription products. 
N-acetil-p-aminophenol undergoes a complex transformation 
by the liver drug metabolizing system see Fig. (2). 5-15% of the 
drug is metabolized by CYP, and in particular by the isoforms 2E1, 
1A2 and 3A4. This reaction gives rise to N-acetyl-3,4-
dihydroxyaniline, that may be excreted, and to a toxic compound, 
N-acetyl-p.benzoquinoneimine (NADPQI), mainly responsible for 
toxicity and for acute liver disease due to acetaminophen Fig. (2a, 
2b). A fraction of acetaminophen, accounting in the adult for 20-
40%, undergoes phase two enzymes transformation, resulting in 
sulphation and glucuronidation see Fig. (2). The intermediate toxic 
compound NADPQI may be inactivated by reduced glutathion 
(GSH), which metabolizes it to mercapturic acid, that may be 
excreted through urine. In the absence of sufficient cellular stores of 
GSH, the toxic compound gives rise to covalent bindings with 
proteins, leading to cell death of hepatocytes and to fulminant 
hepatitis. Acetaminophen metabolism and elimination kinetics in 
neonates are markedly different as compared to children and adult 
subjects, due to the decreased glucuronidation of the drug, a 
substrate for UGT1A6 and UGT1A9, two isoforms of UGT, 
peculiar maturational profile of which has relevant pharmacokinetic 
consequences in drug metabolism in the perinatal period [124]. 
These age-related differences are attributable to biochemical 
differences in young children and, in particular, in newborns. In 
fact, the metabolic profile at birth is characterized by sulphation 
predominating over glucuronidation, probably contributing to less 
formation of toxic metabolites Fig. (2b). In addition, neonates have 
a greater capacity to sinthesize glutathione, thereby inactivating 
toxic metabolites of acetaminophen more effectively [125]. The last 
peculiarity of acetaminophen metabolism in newborns, and in 
particular in preterms, is the low activity of some isoforms of CYP, 
including CYP2D6 whose values are less than 3-5% of adult levels 
at birth. Their scarcely developed activity might be responsible for 
the minor production of the toxic metabolyte NADPQI, mainly 
responsible for acute liver disease Fig. (2).  
In a retrospective metanalysis carried out on 9,337 patients, 
including children and adults, undergoing repeated use of 
therapeutic dosage of acetaminophen, 96 subjects (1.0%) showed 
elevated serum levels of aminotransferase, exceeding the upper 
limit of normal values, one underwent liver transplantation and six 
(0.06%) died of liver failure. On the other hand, prospective studies 
indicate that true therapeutic acetaminophen dosages may slightly 
increase serum aminotransferase activity, but do not cause acute 
liver failure or death, indicating that the reported cases of acute 
severe (fulminant) liver disease might be related to inadvertent 
overdose of the drug [126]. In recent years, several cases of 
acetaminophen-related liver failure have been reported in newborns 
[127] and in infants [128]. In a study on the causes of 348 cases of 
acute liver failure in children, acetaminophen toxicity was found to 
be the most frequent cause of hepatic toxicity, representing 14% of 
diagnoses [129]. The severity of acetaminophen-induced acute liver 
disease in infants and children may be unpredictable, ranging from 
a slight increase in the serum levels of aminotransferases [126] up 
to acute hepatic failure, sometimes associated with encephalopathy 
in newborns [127, 128].  
 
 
Fig. (2). (a) Metabolism of acetaminophen in the adult. (b) Metabolism of 
acetaminophen in the newborn. 
 
As for the mechanism of cell death in acetaminophen 
hepatotoxicity, the mode of cell death in acetaminophen-induced 
acute liver failure remains controversial. Many authors have 
claimed that caspase-dependent apoptosis should be considered at 
the origin of liver disease caused by acetaminophen overdosage 
[130, 131]. Other authors did not find any morphological evidence 
of liver cell apoptosis and, on the contrary, reported liver cell 
ballooning and necrosis in mice treated with acetaminophen [132]. 
The histological picture in liver biopsies from patients with 
acetaminophen-related fulminant hepatitis is characterized by 
diffuse apoptosis of the vast majority of hepatocytes, also defined 
as confluent coagulative cell death, responsible for liver failure.  
In cases of less severe adverse reaction to acetaminophen, the 
histological picture of liver biopsy is characterized by zonal 
hepatocytic cell death, mainly localized in the perivenular areas 
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(zone 3). In these patients, the association with epithelioid non 
caseating granulomas gives a picture very similar to that typically 
found in sarcoidosis [133]. 
At histology, combined hepatocellular and cholestatic injury 
have been reported following acetaminophen intoxication [72]. 
Recently, acetaminophen has been shown to induce infiltration of 
liver parenchyma by macrophages derived from circulating 
monocytes, characterized by the ability to phagocitose apoptotic 
cells and to cause apoptosis of neutrophils, often characterizing the 
histological picture of acetaminophen-inducible liver disease [134]. 
Macrophages and neutrophils have been hypothesized to play 
opposite roles in acetaminophen-induced liver disease: 
macrophages produce heme oxygenase, which is thought to have a 
protective role, whereas neutrophils express indicible nitric oxide 
synthase (iNOS), which is presumed to be an aggravating molecule 
for acetaminophen-induced acute liver failure. The balance between 
these two molecules may determine the outcome of liver disease 
caused by acetaminophen [135]. 
The intimate molecular mechanism whereby the drug causes 
liver cell death has not been completely clarified. Generally, 
acetaminophen-related liver injury has been included among 
intrinsic reactions, being dose-dependent and reproducible in 
experimental animals. Recently, acetaminophen hepatotoxicity has 
been reported to be enhanced in mice by the inflammatory stress 
induced by exposure to bacterial lipopolysaccharide (LPS), which 
significantly lowers the acetaminophen dose sufficient to cause 
acute liver failure. On the basis of these data, it has been 
hypothesized that a sporadically occurring inflammatory episode 
could shift hepatotoxic doses of acetaminophen into the therapeutic 
range, resulting in a idiosyncratic reaction [67]. The hypothesis that 
environmental and extrinsic factors might influence liver toxicity of 
acetaminophen has been recently confirmed by the finding that 
administration of anti-interleukin-1 antibodies attenuates 
acetaminophen-induced liver injury, and that administration of 
recombinant human interleukin-1-receptor antagonist (rhIL-1Ra) 
could dramatically reduce the death of hepatocytes, increasing 
survival rate of mice with acute liver failure induced by 
acetaminophen [130]. Administration of acetaminophen has been 
shown to induce intrahepatic interferon-gamma expression, leading 
to hyphotisize that IFN-gamma could be responsible for 
acetaminophen-induced liver injury, by mediating leukocyte 
infiltration and hepatocyte cell death [136]. The recent report of 
acute liver failure as a result of administration of acetaminophen at 
the maximum recommended daily dose in adults affected by 
malnutrition and/or low body weight, indicates that some patients 
may have increased susceptibility to acetaminophen toxicity even to 
therapeutic doses [137]. Recent data on the efficacy of N-
acetylcysteine (NAC) in subjects with acetaminophen-induced liver 
failure, strongly support the assumption that glutathione deficiency 
is the crucial point in determining diminished capacity to neutralize 
N-acetyl-p-benzoquinone imine, leading to massive hepatic cell 
death [138]. 
Metabolomics, pharmacogenetics, proteomics and 
transcriptomics are more recent areas of study that have been 
applied to for further understanding of DILI. Despite recent 
advances in our understanding of DILI, many aspects of its 
pathophysiology and clinical impact remain unclear. In addition, 
genomic-based studies are evolving concepts, which undoubtedly 
continue to contribute to our comprehensive understanding of the 
underlying mechanisms of drug-induced liver injury [139].  
New exciting data are derived from metabolomic studies. 
Metabolomics might therefore be considered analogous to a “liver 
profile” test in clinical pathology, except that metabolomics 
includes measurement of metabolites present at much lower 
concentrations and, accordingly, provides several orders of 
magnitude greater sensitivity. It seems practicable that, in the more 
distant future, metabolomics will help genomics to revolutionize 
and individualize drug therapy [140, 141]. 
The major pre-drug compounds in the pretreatment of urine that 
were associated with postacetaminophen hepatotoxicity were 
taurine, trimethylamine- N-oxide (TMAO), and betaine. The levels 
of these metabolites were associated with different classes of 
hepatic histology. NMR-based metabolomic profiles of urine 
samples collected prior to dosing were found to significantly 
correlate with the extent of liver injury observed subsequently in 
each rat (good and poor responders). Metabolic bioactivation, 
glutathione depletion and covalent binding are the early hallmark 
events after acetaminophen overdose. Serum metabolomics of 
acetaminophen-induced hepatotoxicity revealed that the CYP2E1-
mediated metabolic activation and oxidative stress following 
acetaminophen treatment can cause irreversible inhibition of fatty 
acid oxidation, potentially through suppression of PPARr-regulated 
pathways [34]. Chen et al. identified long-chain acylcarnitines as 
early biomarkers of acetaminophen- induced hepatotoxicity [142]. 
Another important aspect in prediction of the response to drugs 
is linked to the endogenous metabolome from gut bacteria. In a 
study of healthy human volunteers given a single oral dose of 
acetaminophen, those with high predose levels of p-cresol-sulfate in 
their urine tended to have reduced urinary elimination of the sulfate 
metabolite. p-Cresol is known to be produced by gut bacteria. The 
authors concluded that the p-cresol coming from the gut via 
enterohepatic circulation competed with the acetaminophen in the 
liver for sulfation [143]. 
Recent toxicological studies have been performed on rats using 
metabolomics in association with routine clinical chemistry and 
histopathology. Targeted bile acid analysis, based on LC-MS 
metabolomics data demonstrated increased levels of conjugated or 
unconjugated bile acids in response to individual compounds, did 
not provide earlier detection of toxicity as compared to 
conventional parameters, but may allow distinction of different 
types of hepatobiliary toxicity [144].  
However, to our knowledge, no data are available, in this field, 
for newborns, although metabolomics seem very useful for 
newborns in the next future [145, 146]. 
4.3. NSAIDs 
Nearly all NSAIDs have been implicated in causing liver injury, 
comprised the new selective COX-2 inhibitors. Diclofenac and in 
particular sulindac have been reported to be commonly associated 
with hepatotoxicity, and several NSAIDs such as ibufenac have 
been withdrawn due to their liver toxicity [147]. NSAIDs are a 
heterogeneous group of agents that inhibit synthesis of 
prostaglandins via blockade of the cyclooxigenase (COX) enzymes. 
Various NSAIDs are being extensively used in newborns and, in 
particular, in preterm infants. They are universally used as 
antipyretics and analgesics in infants, even though the efficacy and 
safety in neonates have been poorly studied [148]. Intravenous 
indomethacin and ibuprofen are standard therapies worldwide for 
closure of patent ductus arteriosus [149, 150]: the mechanism of 
action of NSAIDs favouring the closure of ductus arteriosus, is 
related to their ability to inhibit prostaglandin synthesis [151].  
The principal target organ of NSAIDs-related toxicity in 
neonates is kidney, in which prostaglandins, and in particular 
PGE2, play a homeostatic role through their protective vasodilatory 
action against the elevated levels of vasoconstrictive angiotensin II 
that are present in the neonate [152].  
Introduced in clinical practice in 1976 for the therapy of patent 
ductus arteriosus in preterm newborns, indomethacin achieves the 
closure of ductus arteriosus in 80% of infants of 28 weeks or more 
[153]. However, important side effects have been reported, during 
the years, in newborns treated with indomethacin [154]. 
Indomethacin has been shown to induce, by a vasoconstrictor 
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effect, a significant reduction in cerebral, mesenteric and renal 
blood flow [155, 156]. The major consequence of the reduction in 
mesenteric blood flow is an increased risk of developing 
necrotizing enterocolitis [157, 158]. Indomethacin-related liver 
disease is characterized by steatosis, mainly localized in the 
perivenular regions (zone 3 of the acinus). Steatosis is, in the 
majority of cases, macrovesicular and diffused: the vast majority of 
hepatocytes contain a large cytoplasmic fat droplet that displaces 
the nucleus to the periphery of the cell [72]. Steatosis is often 
accompained by liver cell necrosis, which may be zonal or massive 
and diffused [159]. Rare cases of fulminant hepatitis due to 
indomethacin have been reported [160], one of them in a child 
[161]. 
Due to these side effects of indomethacin, another cyclo-
oxigenase inhibitor, a derivative of ibufenac, ibuprofen, emerged. A 
large number of randomized studies comparing the two drugs 
showed the same efficacy for the closure of the patent ductus 
aretriosus [162, 163]. Moreover, the use of ibuprofen has 
demonstrated fewer side effects on the renal, mesenteric and 
cerebral blood flows [164]. However, some cases of pulmonary 
hypertension have been reported after ibuprofen treatment in very 
preterm infants [165].  
As for hepatotoxicity, ibuprofen has been proven to have a 
lower incidence of liver disease as compared to indomethacin, even 
though rare cases of fulminant hepatitis requiring liver transplant 
have been reported [166]. Two cases of cholestatic hepatitis with 
bile duct lesions due to ibuprofen, followed by a destructive process 
of intrahepatic bile ducts ending in vanishing bile duct disease, have 
been described, one of them in a child [167, 168]. The prolonged 
use of ibuprofen has been associated with a higher risk of 
enterocolitis and with changes in renal function [169]. Dramatic 
reduction in urinary PGE2 concentrations after ibuprofen treatment 
has been described in preterm infants with patent ductus arteriosus 
[152].  
4.4. Acetylsalicilic Acid 
Acetylsalicylic acid first undergoes transformation in blood, 
where it is metabolized to salicylic acid by ASA-esterase see Fig. 
(2). In the hepatocyte, salicylic acid undergoes complex 
biotransformations, by phase 1 and phase 2 enzymes. In particular, 
CYP enzymes give rise to hydroxylation, with formation of 2,3 and 
2,5 dyhydroxy benzoic acid, which are metabolized to 
hydroquinone and catecol, two highly hydrophilic compounds 
which are easily excreted through urine. Another fraction of 
salycilic acid undergoes glycine conjugation, giving rise to 
salyciluric acid. A third fraction of salycilic acid ingested 
undergoes glucuronidation by UDP, giving rise to glucuronide 
acylic and glucuronide phenolic Fig. (3a). The peculiarities of the 
drug metabolizing system at birth, are responsible for a peculiar 
metabolism of acetylsalicylic acid in the neonate Fig. (3b): this is 
characterized by the prevalence of enzymes deputed to glycine 
conjugation, responsible for the higher production of salyciluric 
acid, and by decreased production of CYP enzymes and of UDP 
Fig. (3b).  
Liver disease associated with aspirin therapy is, in the vast 
majority of cases, clinically mild and reversible, with hepatocellular 
damage revealed by increased AST/ALT serum levels and bilirubin 
levels mildly elevated, jaundice being present in less than 5% of 
affected individuals [170]. Liver biopsy shows the presence of a 
mild lymphomonocytic infiltrate in portal tracts, associated with 
foci of intralobular liver cell necrosis [171]. The mechanism of 
acetylsalicylic acid hepatotoxicity might be due to the saturation, in 
children, of the major metabolic pathways leading to transformation 
of acetylsalicylic acid into salicyluric and salicylphenolic 
glucuronide, followed by the accumulation of minor metabolites, 
that could be the responsible for hepatic injury and liver disease 
[170]. In children affected by viral infections, including influenza 
and varicella, the acetylsalicylic acid use has been associated with 
the insurgence of Reye syndrome, characterized by diffuse and 
severe microvesicular steatosis, associated with encephalopathy 
[172-174]. Even though the intimate mechanism by which aspirin 
interacts with the viral infection to cause the diffuse microvesicular 
steatosis and encephalopathy is, at the best of our knowledge, 
unexplained, the main physiopathological hypothesis is a 
mitochondrial metabolism insult, eventually causing acute liver 
failure and liver transplantation [175]. On the basis of these data, 
the use of aspirin in children under 12 affected by viral infection 
has been banned in the United Kingdom since 1986 [176] and 
warnings about use of salicylates in children with influenza or 
varicella have led to a sharp decline in the number of children 
reported to have Reye’s syndrome, which is now very rare [177, 
173]. According to a recent article on Reye’s syndrome, it remains 
little-known, the causes of the disease are still unclear, and it can 
still not be proved irrefutably whether administration of 
acetylsalicylic acid is a factor in the development of Reye’s 
syndrome [172]. 
 
 
Fig. (3). (a) Metabolism of acetylsalicilic acid in the adult. (b) Metabolism 
of acetylsalicylic acid in the newborn. 
Antiepilectic Drugs 
Pharmacokinetic differences between neonates, children and 
adults have been reported to affect the absorption, distribution, 
metabolism and excretion of antiepileptic drugs, like many other 
drugs [8].  
10    Current Medicinal Chemistry,  2012 Vol. 19, No. 1 Faa et al. 
Valproic acid (VPA) therapy has been reported to be associated 
with liver disease, revealed by elevation of liver function tests in 
15-30 % of patients, most cases occurring in children younger than 
2 years. VPA-related hepatotoxicity was associated with an increase 
in the formation of oxidative metabolites in children, compared 
with adults [178, 179]. While in the vast majority of cases elevation 
of serum levels of transaminases is a transient phenomenon, 
occasional cases of fulminant hepatitis following VPA therapy have 
been reported [180, 181], predominantly in young children [182]. 
The histological picture of VPA-related liver disease is 
characterized by diffuse microvesicular steatosis associated with 
apoptosis and lytic necrosis of hepatocytes, in the absence of 
significant signs of inflammation. Many hypotheses have been 
proposed during the years regarding the pathogenesis of the 
hepatotoxicity of VPA, including preexisting mitochondrial disease 
[183], associated inborn metabolic defects [184], inhibition of 
mitochondrial beta-oxidation [185], and toxicity from the 
unsaturated metabolites 4-ene-VPA and 2,4-diene-VPA [186]. A 
study on the serum metabolite pattern of VPA infants under therapy 
with the drug, revealed higher concentration ratios of 4-ene-VPA to 
VPA [187]. Moreover, the formation of the hepatotoxic metabolite 
of VPA increased in patients under polytherapy with phenytoin, 
carbamazepine, and stiripentol [188]. 
Valproate has been also associated with the hypersensitivity 
syndrome described in children under therapy with the 
anticonvulsant lamotrigine (LTG) [189, 190]. VPA could inhibit the 
UGT1A4-catalyzed formation of LTG- glucuronide, resulting in an 
increased CYP-dependent formation of the toxic metabolite arene 
oxide intermediate, mainly responsible for the idiosyncratic 
reaction to LTG [191]. 
Phenobarbital, despite its widespread use in NICU as an 
anticonvulsant and as enzyme inducer, has been associated only 
rarely to drug-related liver disease. Only one case of massive 
hepatic necrosis after administration of phenobarbital has been 
reported, to the best of our knowledge, in the literature [192].  
Miscellanea 
Nevirapine, a non-nucleoside inhibitor of human 
immunodeficiency virus type-1 reverse transcriptase, is used in 
highly active antiretroviral therapy combination regimens for the 
treatment of HIV infection and, in particular, for the prevention of 
mother-to-child HIV transmission [193]. Nevirapine antiretroviral 
therapy has been frequently associated with the insurgence of 
severe hepatotoxicity, including cases of fulminant hepatitis with 
liver failure [194]. Major adverse reactions, including 
hepatotoxicity, occur in approximately 3% of HIV-infected 
individuals who receive long-course nevirapine-containing 
regimens, with higher rates being noted among females [195]. 
Short-course nevirapine for HIV prophylaxis is associated with 
fewer hepatotoxic reactions for HIV-infected women and their 
offspring, but administration for more than two weeks is associated 
with higher rates of liver toxicity in pregnant mothers and in their 
children [196]. The histological picture of liver disease related to 
nevirapine toxicity was chracterized, in cases with good prognosis, 
by cholestasis with bile canalicular plugs, mainly concentrated in 
the zone 3 of the liver acinus, associated with portal infiltrate of 
eosinophils, in the absence of significant hepatocellular necrosis 
[194]. In rare cases, liver biopsy revealed the presence of extensive 
liver cell necrosis, extending from the periterminal areas (zone 3 of 
the acinus) towards the portal tracts, giving rise to bridging 
necrosis, asociated with portal infiltration by eosinophils and 
lymphocytes, clinically corresponding to fulminant hepatitis [196]. 
Methanphetamine, better known as ectasy, is one of the fastest 
growing illicit drugs in United States and in Europe. It has been 
recognized as a common cause of severe acute drug-related 
hepatitis in adults [197]. The clinical picture is characterized, in the 
vast majority of patients, by a strict similarity to the typical acute 
viral hepatitis [198], even though a marked variability in the clinical 
expression of ectasy-induced liver disease has been reported [199]. 
In rare cases, the use of methanphetamine has been recognized as 
the main cause of fulminant hepatitis [200]. Recently, prenatal 
exposure to methanphetamine has been identified as the cause of 
acute hepatitis with severe bilirubinostasis in a newborn born to a 
mother dependent on drugs, and with positivity for 
methanphetamine test in the urine [201]. 
CONCLUSIONS 
Dosing, timing, and route of administration must take in careful 
consideration the marked variability of neonates, particularly of 
preterms and of low birth weight newborns, regarding 
bioavailability, distribution, metabolism, biotransformation and 
excretion to achieve the maximum efficacy and limit the always 
possible adverse effects [202]. Developmental changes in liver 
xenobiotics’ metabolism, and in particular in drug metabolism, 
should be considered as a major factor responsible for the marked 
differences in drug-related hepatotoxicity between newborns, 
children and adults. The peculiar frequency and degree of 
hepatotoxicity from many drugs in neonates may be easily 
explained by an imbalance between the generation of toxic 
metabolites in the hepatocytes, and the immaturity at birth of the 
detoxification processes.  
In summary, drug metabolism in neonates shows many 
peculiarities and marked differences as compared to the hepatic 
metabolism in adults. This appears to be mainly due to the 
immaturity at birth, and in particular in preterm newborns, of the 
hepatic drug metabolizing system. This immaturity results in the 
accelerated metabolization and excretion of some drugs, and in the 
decreased metabolization of other drugs, with significant 
consequences in clinical practice. The evidences on the rapid 
maturation of the different drug metabolizing enzymes during the 
perinatal period are at the basis of continuous changes, day by day, 
in the ability to metabolize drugs in the same neonate, adding new 
difficulties regarding the decisions taken on dosing of each drug 
employed. All these data clearly indicate personalized medicine as 
the main target of any neonatologist, considering the interindividual 
variability in the maturity of the drug metabolizing system, even 
among subjects showing the same gestational age at birth.  
Finally, we want to emphasize the need for educational 
initiatives in NICU centers aimed at increasing the neonatologists’ 
awareness of the usefulness and the limitations of the widely used 
drugs in the neonate, and at favouring appropriate risk 
comunication strategies in order to avoid both adverse liver effects 
and unjustified interruption of therapies. Multicenter referral 
networks enrolling children with suspected DILI according to 
standardized methodologies are needed. These networks should 
also provide crucial insights into the mechanism(s) of DILI, with 
the ultimate aim of preventing future cases of drug-related hepatitis 
and drug-related deaths in the newborn.  
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